Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Oral Methylated N-Aryl Chitosan Derivatives for Inducing Immune Responses to Ovalbumin

Tittaya Suksamran1, Jariya Kowapradit1, Tanasait Ngawhirunpat1, Theerasak Rojanarata1, Warayuth Sajomsang2, Tasana Pitaksuteepong3, Praneet Opanasopit1

1Pharmaceutical Development of Green Innovations Group (PDGIG), Faculty of Pharmacy, Silpakorn University, Nakhon Pathom; 2National Nanotechnology Center, Thailand Science Park, Pathumthani; 3Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.

For correspondence:-  Praneet Opanasopit   Email: praneet@su.ac.th   Tel:+6634255800

Received: 8 April 2012        Accepted: 5 November 2012        Published: 13 December 2012

Citation: Suksamran T, Kowapradit J, Ngawhirunpat T, Rojanarata T, Sajomsang W, Pitaksuteepong T, et al. Oral Methylated N-Aryl Chitosan Derivatives for Inducing Immune Responses to Ovalbumin. Trop J Pharm Res 2012; 11(6):899-908 doi: 10.4314/tjpr.v11i6.5

© 2012 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate different structures of modified chitosan containing different chain lengths and aromatic moieties for vaccine delivery capacity.
Methods: The characteristics of the modified chitosan, namely, methylated N-(4-N,N-dimethylaminobenzyl) chitosan (TM-Bz-CS), methylated N-(4-N,N-dimethylaminocinnamyl) chitosan (TM-CM-CS) and methylated N-(4-pyridinylmethyl) chitosan (TM-Py-CS), with Eqiva degree (equivalent degree) were studied by in vitro absorption enhancement on the transepithelial electrical resistance (TEER) in Caco-2 cell monolayers as well as by in vivo adjuvant activity against ovalbumin (OVA), a model antigen, via oral administration to BALB/c mice.
Results: At the same concentration and pH (0.1 mg/ml, pH 7.4), TM65CM50CS exhibited the highest in vitro enhancing paracellular permeability and also the highest in vivo adjuvant activity following oral administration to mice. OVA-specific serum immunoglobulin G (IgG) antibody levels of mice that received OVA in TM65CM50CS were significantly (p < 0.05) higher than those that received OVA in TM65CS, TM56Bz42CS and TM53Py40CS. On the other hand, TM65CS and TM56Bz42CS exhibited in vitro enhancing paracellular permeability but showed no immune responses, while TM53Py40CS failed to enhance paracellular permeability and did not elicit immune responses as well.
Conclusion: This study demonstrates that addition of hydrophobic moiety (dimethylaminocinnamyl) to CS backbone can increase both its absorption enhancing property and adjuvant activity. The chemical structure and the positive charge location play an important role for binding affinity, absorption enhancement and immune responses.

Keywords: Chitosan derivatives; Absorption enhancement; Oral vaccine delivery; Immunoadjuvants; Ovalbumin

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates